Federal Health Review Finds Cannabis Helps Some Chronic Pain—But Side Effects Depend on THC-CBD Balance
The latest federal review found that balanced THC:CBD cannabis products provide modest but measurable relief for chronic pain and physical function.
High-THC cannabis products may reduce pain, but they also produce significantly more dizziness, sedation, and nausea.
CBD-dominant products did not consistently improve chronic pain outcomes in current clinical evidence.
Cannabis is not a universal pain solution. Outcomes depend heavily on cannabinoid ratios, dosing, and patient biology.
The strongest evidence supports carefully formulated cannabinoid therapies rather than generalized cannabis use.
Long-term questions about opioid reduction, cognition, dependence, and psychiatric risk remain unresolved.
A 2025 update from the Agency for Healthcare Research and Quality (AHRQ) found that balanced THC:CBD cannabis products can modestly reduce chronic pain and improve function, though side effects like dizziness and sedation are common. CBD alone showed little consistent benefit for chronic pain in current clinical trials.
Chronic pain is one of modern medicine’s most stubborn failures. More than 100 million Americans live with persistent pain, and the economic burden exceeds $500 billion annually through healthcare costs and lost productivity (https://www.ncbi.nlm.nih.gov/books/NBK92521/). That scale of suffering explains why cannabis has moved from cultural controversy into serious medical investigation.
“The chronic pain crisis is not just a medical issue. It is a systems-level failure affecting quality of life, productivity, and mental health.”
The question, though, is no longer whether cannabis has biological activity. It clearly does. The real question is whether cannabinoids provide meaningful, sustainable pain relief under rigorous clinical scrutiny.
That’s where the Agency for Healthcare Research and Quality enters the picture.
The AHRQ has been conducting a “living systematic review” of cannabis and chronic pain. Unlike traditional reviews that freeze in time, a living review continuously incorporates newly published studies to keep conclusions current.
“A living review is not static evidence. It is evidence that evolves alongside the science.”
The latest 2025 update evaluated randomized clinical trials and observational studies examining cannabis-based interventions for chronic pain.
The findings are nuanced rather than revolutionary.
The strongest evidence supported products containing relatively balanced THC and CBD ratios.
“Balanced cannabinoid formulations appear more clinically useful than THC-heavy or CBD-only approaches.”
Patients using these formulations experienced modest improvements in pain intensity and daily function. The benefits were not dramatic, but they were measurable and clinically relevant for some individuals.
Importantly, the improvement came with trade-offs.
Dizziness, sedation, and nausea occurred frequently. Dizziness, in particular, emerged as one of the most consistent adverse effects across studies.
This aligns with broader cannabinoid pharmacology research showing THC influences motor coordination, alertness, and sensory processing through CB1 receptor activation in the central nervous system (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877694/).
“Cannabinoids do not eliminate pain. They alter how the nervous system processes it.”
High-THC formulations also demonstrated modest pain relief, but side effects became substantially more pronounced.
“More THC does not necessarily mean more relief. It often means more impairment.”
Patients reported increased sedation, nausea, and cognitive dulling. The evidence supporting high-THC products was also less consistent overall.
This distinction matters because much of the public conversation around cannabis still assumes potency equals effectiveness. Clinically, that relationship appears far more complicated.
THC primarily activates CB1 receptors in the brain, influencing pain perception, mood, coordination, and memory (https://pubmed.ncbi.nlm.nih.gov/18404144/). While that can reduce discomfort, it can also create functional impairment.
CBD-dominant products delivered perhaps the most surprising result for many consumers: they generally failed to produce reliable improvements in chronic pain outcomes.
“CBD is biologically active, but current evidence does not support it as a consistently effective standalone treatment for chronic pain.”
That does not mean CBD lacks therapeutic value. Research suggests CBD influences inflammation, serotonin signaling, and stress pathways (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604171/). But the current clinical data for chronic pain remains inconsistent and underwhelming.
This gap between public perception and evidence highlights an important reality in cannabinoid medicine: popularity is not proof.
The newest review added six additional studies, including:
Topical hemp seed oil versus diclofenac gel for osteoarthritis
THC/CBD/CBN topical formulations for diabetic neuropathy
Inhaled cannabis compared directly against oxycodone in fibromyalgia patients
Even with these additions, the broader conclusions stayed largely unchanged.
“New studies expanded the map, but they did not fundamentally redraw it.”
The evidence base now includes 29 randomized trials and 15 observational studies, yet balanced THC:CBD formulations remain the most promising category.
The most important part of the review may actually be the unanswered questions.
“We now know cannabinoids can modestly reduce chronic pain. We still do not fully understand the long-term consequences of doing so.”
There remains limited evidence regarding:
Long-term opioid reduction
Cannabis use disorder risk
Cognitive decline
Psychosis risk in chronic pain populations
Long-term functional outcomes
This uncertainty matters because chronic pain treatment is not about short-term symptom suppression alone. It is about sustainability, safety, and preserving quality of life over years or decades.
Cannabis is neither miracle cure nor medical fraud. The evidence now points somewhere more mature and more realistic.
“Cannabis appears most useful when treated as a precision tool rather than a universal remedy.”
Balanced THC:CBD formulations show modest but legitimate benefit for some chronic pain patients. High-THC products carry higher burdens of side effects. CBD alone has yet to demonstrate consistent efficacy.
The most responsible position is neither hype nor dismissal. It is disciplined curiosity guided by evolving evidence.
That may not fit neatly into headlines, but it’s where the science currently stands.
Current evidence suggests balanced THC:CBD cannabis products can modestly reduce chronic pain and improve physical function in some patients. Benefits are generally moderate rather than dramatic and often come with side effects like dizziness or sedation.
According to the latest AHRQ review, CBD-dominant products have not consistently demonstrated meaningful pain relief in clinical trials. More research is needed to determine whether specific doses or formulations may work better for certain conditions.
Matthew Myro Rothman is Chief Science Officer and VP of Marketing at EM2P2 and CannaLnx, where he helps bridge medical cannabis, healthcare infrastructure, patient education, and emerging technology. A lifelong musician, writer, philosopher, and cannabis science expert, Matthew spent more than 15 years working in cultivation, consulting, and medical cannabis operations throughout California before returning to Ohio to help shape the future of intelligent cannabis medicine. He holds a graduate degree in Philosophy, Cosmology, and Consciousness from California Institute of Integral Studies and writes extensively on cannabis science, consciousness, wellness, and human performance.
Please note: You are not currently logged in. Only members can contribute comments. If you would like to contribute click the button below.
